What Changed
OptimizeRx, headquartered in Waltham, Massachusetts and trading on Nasdaq under the ticker OPRX, announced on September 14, 2026 that it has expanded its Natural Language Audience Builder (NLAB) to allow building both HCP and DTC audiences in the same workflow.
The expansion also added Micro-Neighborhood Targeting (MNT) audiences to NLAB.
OptimizeRx describes its platform offering as the Dynamic Audience Activation Platform (DAAP) together with Micro-Neighborhood Targeting (MNT).
MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level.
Highlights
- OptimizeRx expanded its Natural Language Audience Builder (NLAB) to allow building both HCP and DTC audiences in the same workflow.
- Micro-Neighborhood Targeting (MNT) audiences were added to NLAB.
- MNT audiences combine de-identified clinical and consumer data at the ZIP-9 level.
- OptimizeRx trades on Nasdaq under the ticker OPRX and is headquartered in Waltham, Massachusetts.
Who Is Affected
“The more complexity NLAB removes for DSPs, agencies, and their life sciences clients, the easier it becomes to put sophisticated audience intelligence to work.”
“Life sciences marketers need audiences grounded in real healthcare behavior relevant to their brand, not generic segments or modelled proxies.”
- Louis Trivento holds the title SVP Strategic Partnerships at OptimizeRx.
- Jennifer Dinkel holds the title SVP Marketing at OptimizeRx.
- Douglas Farrell serves as Investor Relations Contact for LifeSci Advisors, LLC.
What To Watch Next
OptimizeRx's announcement, dated September 14, 2026, references its Annual Report on Form 10-K for the year ended December 31, 2025.